image: News/Press Releases
18 November 2004
Oxford Diffraction Raises Expansion Funding.
Oxford Diffraction Limited secures expansion funding from existing investors TTP Ventures and a new investor Enterprise VCT plc (advised by Noble Fund Managers).

11 September 2004
Universität zu Lübeck to use an Oxford Diffraction Xcalibur PX Ultra system for Crystal Structural Studies of SARS Virus Proteins
The Institut für Biochemie at the Universität zu Lübeck, Germany, acquires an Xcalibur PX Ultra system to accelerate its structural biology programme focusing on the SARS virus

26 August 2004
Oxford Diffraction launches GEMINI – the complete service diffractometer – at ECM22
Oxford Diffraction Limited launched its new “Gemini” product at the European Crystallographic Meeting (ECM22) in Budapest this week. Gemini's defining features are co-mounted molybdenum and copper X-ray sources.

12 July 2004
R&D magazine have announced Oxford Diffraction's Xcalibur PX Ultra protein crystallography system as one of 2004's top 100 technologically significant new products and winner of the prestigious ‘R&D 100’ award.

24 June 2004
The Structural Genomics Consortium in Oxford becomes a protein crystallography reference site for Oxford Diffraction
The Structural Genomics Consortium (SGC) in Oxford, UK, has agreed to become the local reference site for Oxford Diffraction Limited for its novel Xcalibur PX Ultra protein crystallography product.

1 November 2003
Oxford Diffraction relocate to new premises
Due to ongoing rapid growth, Oxford Diffraction Limited has moved its head offices to a smart new site in the Oxfordshire region.

22 May 2003
Oxford Diffraction Launch Platinum Level US Reference Site for Crystallography at Virginia Tech
The current “Gold Level Reference Site” at Virginia Tech will now be promoted to the top “Platinum Level”, with the installation of a third Xcalibur, the innovative new Xcalibur PX Ultra.

15 September 2003
Johann Wolfgang Goethe-Universität, Frankfurt, becomes German reference site for Oxford Diffraction
The Institute of Minerology/Crystallography at the Johann Wolfgang Goethe-Universität, in Frankfurt am Main, become a Silver reference site for recently launched Xcalibur 3 single crystal X-ray diffractometer.

21 January 2003
Oxford Diffraction Limited Announce Collaboration with York Structural Biology Laboratory to Evaluate New Protein Crystallography X-ray Diffractometer
The York Structural Biology Laboratory (YSBL) and Oxford Diffraction Limited have today signed a heads of agreement to evaluate a new X-ray diffractometer, “Xcalibur PX Ultra”, intended for protein crystallography.

11 October 2002
Oxford Diffraction Launch Gold Level US Reference Site for Crystallography at Virginia Tech
Virginia Tech agrees Gold Reference Site with Oxford Diffraction as high profile US demonstration facility for single crystal diffractometers.

12 November 2002
Swiss Norwegian Beamline Purchase New Large Area CCD Detector for Six-Circle Synchrotron Diffractometer from Oxford Diffraction Limited
SNBL based at the ESRF synchrotron purchase the “ONYX” large-area CCD to mount on their six-circle diffractometer. The detector will be used for a variety of applications in single-crystal diffraction including protein crystallography.

10 September 2002
Oxford Diffraction launches Xcalibur PX – a compact and cost-effective macromolecular crystallography system
Oxford Diffraction Limited recently launched the “Xcalibur PX” single crystal diffractometer at the XIX IUCr meeting, held in Geneva in August. The Xcalibur PX system marks the entry of Oxford Diffraction Limited into protein crystallography.

7 March 2002
Crystal Cooling to <15 Kelvin : Oxford Diffraction's Helijet put through its paces at the ESRF, Europe's leading Synchrotron
ESRF demonstrate the Helijet's unique technical specifications that allow cooling of single crystals in X-ray diffraction to less than 15 Kelvin.

30 March 2001
Venture Funding for Oxfordshire spin-out to uncover the structure of molecules and proteins
Nearly two million pounds of new equity investment has been injected into an Oxfordshire company formed from a partnership including Oxford Instruments and TTP Ventures.
image: right drop shadow
24 June 2004

The Structural Genomics Consortium in Oxford becomes a protein crystallography reference site for Oxford Diffraction

The Structural Genomics Consortium (SGC) in Oxford, UK, has agreed to become the local reference site for Oxford Diffraction Limited for its novel Xcalibur PX Ultra protein crystallography product.

The SGC in Oxford purchased Xcalibur PX Ultra in February 2004 as a convenient way to screen crystals generated in their high-throughput laboratory. Since its installation in March 2004, Xcalibur PX Ultra has been put through its paces on a variety of protein systems and directly compared to a 5kW rotating anode. From Oxford Diffraction, Dr. Paul Loeffen, CEO, said “We are delighted that a high profile and important institute as the SGC have recognised the unique advantages of Xcalibur PX Ultra as a tool that will contribute to the achievement of their ambitious goals. We look forward to working closely with them in the future as one of our key reference sites”.

The SGC is a not-for-profit organization that aims to determine the three dimensional structures of proteins of medical relevance, and place them in the public domain without restriction. Announced in April 2003, this initiative receives funding from Canadian and British sponsors, from both the public and private sectors - the Wellcome Trust, GlaxoSmithKline, Genome Canada, the Ontario Research and Development Challenge Fund, the Ontario Innovation Trust and the Canadian Institutes of Health Research. The goal of this undertaking is to develop the infrastructure and technologies necessary for rapid, parallel, structure determination, with the aim of having the capability to determine 200 protein structures per year. Over the first four years, the SGC will target 350 proteins that have relevance to human health and disease, such as proteins associated with diabetes, cancer, and infectious disease such as malaria. Targets will also be chosen based on interest from the scientific community, the pharmaceutical industry, expertise within the Consortium and scientific impact.

image: left bottom shadow image: bottom right shadow *
Link to Chinese Version
Copyright © 2008 Oxford Diffraction, all rights reserved
UK company registered number: 4020656
Home: image: home icon
image: top background
image: header